Portfolio AOP Health
Product overview with focus on integrated therapies for rare diseases and in critical care.
Following products are currently available in the UK.
AOP Health's focus is on integrated therapies for rare diseases and in critical care. The portfolio comprises products in the following therapeutic areas: Hemato-oncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Critical Care. AOP Health’s strategic goal is to constantly deliver new treatment options with respect to rare diseases and critical care.
Trepulmix is indicated for the treatment of adult patients with WHO Functional Class (FC) III or IV and - inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or - persistent or recurrent CTEPH after surgical treatment to improve exercise capacity.